WO1983001196A1

WO1983001196A1 - Mixture for human supply of selenium as a trace substance and the use thereof in solutions for storage of organs, in media for cell cultivation and in nutritive solutions for storage of blood components

Info

Publication number: WO1983001196A1
Application number: PCT/SE1982/000304
Authority: WO
Inventors: Erland Johansson
Original assignee: Erland Johansson
Priority date: 1981-10-06
Filing date: 1982-09-30
Publication date: 1983-04-14
Also published as: FI831979A0; DK249683A; ATE17651T1; DE3268851D1; HK95388A; CY1449A; EP0089997A1; FI831979L; EP0089997B1; JPS58501676A; US4784852A; SE8105887L; DK249683D0

Abstract

A composition for human ingestion of selenium as a trace element and comprising a selenium (IV) compound or seleno-methionine + a selenium (IV) compound. The admixture into the composition of Vitamins E, B2?, B6? and B12? allows the body to assimilate selenium. The composition may also be used in solutions for storage of organs, in media for cell cultivation and in nutritive solutions for storage of blood components.

Description

MIXTURE FORHUMAN SUPPLY OF SELENIUM AS ATRACE SUBSTANCE AND THE USE THEREOF IN SOLUTIONS FOR STORAGE OF ORGANS INMEDIAFOR CELLCULTIVATION ANDINNUTRITIVE SOLUTIONSFORSTORAGE OF BLOODCOMPONENTS. The invention concerns a composition designed to ingest the trace element selenium into human beings.

In later years, increasing interest has been drawn to the substances known as trace elements, i.e. elements which are absolutely vital to the human organism, albeit in minute amounts. There are clear indications that many diseases and states of ill-health are a consequence of deficiencies of one or several of such trace elements. For example, there are reasons to suspect that certain heavy metals, such as cadmium, which are dissolved upon their contact with acid, such as through acid rains, cause a rise of the blood pressure. Animal tests have shown that cadmium-induced high blood-pressure conditions may be normalized by selenium compounds. Ingestion of the heavy metal cadmium in animals are inducive to damages to the endothelium. This, jointly with an increased blood-pressure and changes in the cholesterol pattern in the blood are considered the primary factors of arteriosclerosis. According to an American study, individuals having a high blood-pressure showed cadmium contents in erythrocytes which ware double those found in a control group. Expositions in industry to heavy metals together with an excess ingestion of cadmium present in food in combination with a selenium -depleted diet may play important parts in the pathoganesis in this regard. Animal tests (on rats) have shown that iron (aluminium) may trigger off epileptic attacks. When selenium (IV) was ingested with drinking water, no such attacks were triggered off. Patients suffering from epilepsy proved to have low selenium contents in urine. The iron contents in plasma in one patient was considerably increased while the selenium contents were somewhat below the reference amounts. Since high iron contents are considered to start off lipid pβroxidation, supplementation of selenium should reduce this disorder. In cases of prolonged total parenteral nutrition (TPN) food diets having low contents of selenium have proved to cause muscular pain. Ingestion of selenium under certain conditions as will be explained in closer detail in the following, removed these pains completely. Tests have also shown that such muscular diseases as muscular dystrophy, non-specified muscular pains and myositis in many cases are selenium responsive. Also in some multiple-sclerosis patients remarkable improvements from selenium therapy (auto-therapy) have been found. Additionally, attempts to alleviate rheumatoid arthritis by selenium supplementation have given interesting results. Patients suffering from this disease have increased contents of copper in serum whereas the selenium contents are reduced. In selenium therapy (for instance using Mixture 3) care should be taken to ensure that the treatment continues over a prolonged period, allowing saturation of any metallic ion surplus. Copper has an inhibitory effect on the selenium enzyme (GSH-Px), which means that in an initial stage the activity may increase only slowly.

Finland like Sweden is a selenium-deficit area. The death rate in cardio-vascular diseases in Finland is one of the highest in the world. Exposition to heavy metals, such as cadmium (smoking, food), dietary habits can in these cases reduce the contents of selenium in the throrabocytes. Cardio-vascular patients show lower GSH-Px-values in the throrabocytes. This could be expected, in view of the fact that the throrabocytes are the species in the human body that are the richest in selenium. The hypothesis that also myocardial infarction is selenium-deficiency induced lies near at hand. One of the reasons for selenium deficiency probably is the increased acidification of the environment, which causes leaching of the food that normally supplies the body with selenium in edible form, for instance in the form of Se(lV) or seleno-methionine. As mentioned above, acidification causes leaching but some investigations indicate that selenium absorption is reduced also as a consequence of "sulfur competition". Uraemia patients show changed trace element contents in blood, depending on impaired kidney function but. also on contamination from e.g. utensils (cadmium, aluminium) in haemodialysis therapy. An excess mortality rate in coronary-vascular diseases is found in this category of patients. Supplementation of trace elements prior to or after dialysis should reduce the mineral imbalance in the body of uraemia patients.

Epidemiological studies have shown that selenium-deficit areas are oppositely correlated to some forms of cancer, such as cancer of the breast, stomach, colon and rectum. Animal tests have shown that selenium compounds (Na₂SeO₃, seleno-methionine) have a protective effect against selected mammary-carcinogenic, colon -carcinogenic and liver-carcinogenic compounds. Mutagenic studies of carcinogens likewise show that selenium is effective in reducing significantly the mutagenic activity. It is therefore probable that the diet should contain certain amounts of selenium compounds in order to protect human beings against cancer. The protection could exist at several levels: 1) protection against nucleotide peroxides;

2) prevention of imbalance in metal ions;

3) improvement of the infection and immunity defence;

4) facilitation of the microsomale detoxifi cation; 5) anti-oxidant protection against lipid peroxides;

6) radical modulator.

The daily intake should be higher than that recommended by RDA, which is 50-200 μg Se/day. To obtain a cancer-inhibitory efrect it is considered that the intake should be about 200-350μg Se/day.

Treatment of various cancer forms with anticancer compounds, e.g. adriamycine, has considerable negative effects, such as a high cardiac toxicity. Since selenium compounds (Na₂SeO₃, seleno-methionine) have a beneficial effect on some muscular diseases, selenium supplementation (storing) prior to and during treatment with anticancerous preparations felso in combination with radiology treatment) should be effective in reducing some of the negative effects of anticancer coumpounds. Considering that the microsoraal function is affected by selenium deficiency an indrease of the selenium level will contribute additionally to reducing the toxic effect of the carcinocidal substances.

Patients suffering from diabetic cataract have been successfully treated with selenium plus Vitamin E. Animal tests have shown that seleno-methionine is preferable to sodium selenite to treat cataract. Selenium deficiency is assumed to increase the lipid peroxidation and thus result in an increase of pigmentation. Selenium therapy tested on cataract patients in Sweden has given positive results.

The purpose of the invention is to provide a formula by means of which selenium may be ingested in such a form that the body is capable of absorbing selenium as a trace element. For this purpose the invention concerns a composition for human ingestion of selenium as a trace element but also for normalizing imbalance in the mineral status of the body. This composition is characterised in that it contains a selenium (IV) compound or such a compound in combination with seleno-methionine in an amount corresponding to between 50 and 500 μg of selenium, Vitamin E in amounts of between 10 and 100 mg, Vitamin B₂ in amounts of between 1 and 5 mg, Vitamin B₆ in amounts between 2 and 10 mg and Vitamin B₁₂ in amounts between 1 and 5 μg . Owing to this formulation of the composition the body absorbs selenium Se(lV) and seleno -methionine.

As apparent from the dependent claims the composition is to have a certain formulation when intended for pharmaceutical uses. The purpose of the invention is also to prevent selenium deficiency, in which case the compo sition in accordance with the invention is to be ingested as food supplementation and preferably be formulated in accordance with the teachings of Claim 2.

The amounts specified in the claims are intended daily doses for adults of normal weight, and some modifi cation of the daily amounts therefore is possible and sometimes also recαmmendable. The amounts specified therefore are to be regarded as an indication of the mutual relationship between the substances of which the mixture is composed. Tests have further shown that a composition in accordance with the subject invention also has efficient therapeutic effects in relieving and healing inflammatory conditions, that is, to strengthen the body's natural resistance against inflammations of the skin, the effects of surgical operations, microorganism-induced inflammations, virus attacks, and so on.

Much remains to be understood as regards the exact mechanisms connected with Se(lV) and seleno-methionine, but research carried out to date indicate that selenium is of extremely great importance as a trace element in the body and this research suggests that the importance of selenium extends also to many other functions of the body, among them the enzyme production and the effects of enzymes.

Finally, it should be pointed out that the invention is not limited to only the formulations indicated herein but that obviously the addition thereto of further trace elements is possible, in which case it should be understood that it is necessary to ensure that such added elements are compatible with the rest of the substances making up the composition. For instance, admixture of additives facilitating the metal-ion balance in metal-ion-depending enzymes lies within the scope of the subject invention, examples of such additives being manganese, chromium, magnesium and zinc.

The following examples of the composition of tablets are to be regarded as illustrative of the invention and in no way to limit the latter. Food supplementation Example 1 Sodium selenite (Na₂SeO₃.5H₂O) 50 μg(Se(lV))

Vitamin E (α. -tocopheryl acetate) 10 mg

Vitamin B₂ (sodium riboflavine phosphate) 2 mg Vitamin B₆ (pyridoxine chloride) 2 mg

Vitamin B₁₂ (cyancobolamin) 1μg

Fillers, such as magnesium stearate

Dosage: 1 tablet/day. Children, adults Example 2 Sodium selenite (Na₂SeO₃.SH₂O) 25 μg Se

Seleno-methionine 25 μg Se

Vitamin E 10 mg

Vitamin B₂ 2 mg

Vitamin B₆ 2 mg

Vitamin 3_{1 2} 1 μ g

Fillers, such as magnesium stearate Dosage: 1 tab let/day . Child ren , adu lts Therapy Example 1 Sodium se lenite (Na₂SeO₃ . 5H₂O ) 200 μ g Se

Vitamin E (α -tocopheryl acetate) 100 mg Vitamin B₂ (sodium riboflavine phosphate) 2 mg Vitamin B₆ (pyridoxinβ chloride) 2 mg

Vitamin B₁₂ (cyancobolamin) 1 μg

Fillers, such as magnesium stearate Dosage: 1 to 2 tablets/day according to need. 500 μg Se/day should not be exceeded unnecessarily in cases of prolonged therapy. Therapy Example 2 Sodium selenite (Na₂SeO₃.SH₂O) 100 μg Se

Selena methionine 100 μg Se

Vitamin E 100 mg

Vitamin B₂ 2 mg

Vitamin B₆ 2 mg

Vitamin B₁₂ 1 μg

Fillers, such as magnesium stearate Dosage: 1 to 2 tablets/day according to need. 500 μg Se/day should not be exceeded unnecessarily in oases of prolonged therapy.

In cases of pernicious anaemia or leukaemia

(leukaemian conditions) Vitamin B₁₂ should be removed from the composition and be administered according to need as per special prescription.

The tablets should be taken together with food for optimal effect. Large amounts of juice (Vitamin C) should not be taken together with the tablets. Juice may be taken after the absorption of the tablets.

Claims

C l a i m s

1. A composition for human ingestion of selenium as a trace element, c h a r a c t e r i s e d i n t h a t the composition contains a selenium (lV) compound or seleno methionine + a selenium (IV) compound in amounts corresponding to between 50 and 500 μg selenium, Vitamin E in amounts of between 10 and 100 mg, Vitamin B₂ in amounts of between 1 and 5 mg,

Vitamin B₆ in amounts of between 2 and 10 mg, and preferably

Vitamin B₁₂ in amounts between 1 and 5 μg.

2. A composition according to claim 1 for use as food supplementation, c h a r a c t e r i s e d i n t h a t it contains Se(lV) in an amount corresponding to 100 μg selenium,

Vitamin E in an amount of 10 mg, Vitamin B₂ in an amount of 1.5 mg,

Vitamin B₆ in an amount of 2 mg, and preferably

Vitamin B₁₂ in an amount of 2 μg.

3. A composition according to claim 1 for therapeutical uses, c h a r a c t e r i s e d i n t h a t the composition contains Se(lV) or Se(lV) + seleno methionine in an amount corresponding to 200μg selenium, Vitamin E in an amount of 10 mg, Vitamin B₂ in an amount of 1.5 mg,

Vitamin B₆ in an amount of 2 mg, and preferably

Vitamin B₁₂ in an amount of 2 μg.

4. A composition according to any one of the preceding claims, c h a r a c t e r i s e d i n t h a t selenium (lV) is present as Na₂SeO₃.

5. A composition according to any one of the preceding claims, c h a r a c t e r i s e d i n t h a t it contains anti-inflammatory preparations.

6. A composition according to any one of the preceding claims, c h a r a c t e r i s e d i n t h a t it also contains anticancer compounds.

7. Use of the composition according to any one of the preceding claims in solutions for storage of organs.

B. Use of the composition according to any one of claims 1 - 6 in cell-cultivation media. 9. Use of the composition according to any one of claims 1 - 6 in nutritive solutions for storage of blood components.